Regulatory Approval

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

A new maternal blood test claims over 97% accuracy in predicting autism risk, offering hope for early intervention while igniting a fierce ethical debate.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

In a novel proposal, IKE Tech asks the FDA to regulate its AI-powered compliance software, aiming to curb youth vaping with biometric and blockchain tech.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

Aptar Digital Health and Enable Injections are pairing the enFuse® wearable injector with a new digital app to transform self-care for chronic diseases.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

CorTec's brain-computer interface gets FDA Breakthrough status, offering new hope for restoring movement in millions of chronic stroke survivors.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

A new minimally invasive stent for complex aortic arch disease receives FDA approval, offering hope to high-risk patients previously deemed untreatable.

FDA approves a pivotal trial for a novel heart valve, potentially revolutionizing treatment for millions with severe tricuspid regurgitation.

Royal Biologics' new Fibrinet system uses a patient's own blood to create a living bandage, a major step forward for treating diabetic and venous ulcers.

A new AI software that analyzes MRI scans has received a first-of-its-kind FDA classification, promising to help doctors differentiate complex brain disorders.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Lipocine's stock plummets after its PPD drug fails a Phase 3 trial, but a promising signal in a patient subset offers a narrow path forward.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

With FDA approval for a pivotal trial, VDYNE advances its unique valve replacement system, offering new hope for millions with severe tricuspid regurgitation.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.